AXSM Axsome Therapeutics Inc.

+0.43  (+2%)
Previous Close 24.78
Open 25.05
Price To Book 48.48
Market Cap 839,626,865
Shares 33,305,310
Volume 28,653
Short Ratio
Av. Daily Volume 1,242,931

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data met primary endpoint - April 15, 2019.
Smoking cessation
Phase 2/3 top-line data due 1H 2020.
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
Complex regional pain syndrome (CRPS)
Phase 3 data due 2H 2019.
Treatment resistant depression
Phase 3 interim efficacy analysis January 9, 2017 recommended trial continue to full enrollment.
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 top-line data due 2H 2019.
Phase 3 trial to be initiated 2Q 2019 with data due 2H 2019.
Major Depressive Disorder
Phase 2 top-line data due 2H 2019.

Latest News

  1. Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting
  2. Do Institutions Own Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares?
  3. 3 Top Small-Cap Stocks to Buy in June
  4. Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting
  5. These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month
  6. Here's Why You'll Regret Ignoring This Biotech Stock Rocket
  7. Edited Transcript of AXSM earnings conference call or presentation 9-May-19 12:00pm GMT
  8. Axsome Therapeutics, Inc. (AXSM) Q1 2019 Earnings Call Transcript
  9. Axsome: 1Q Earnings Snapshot
  10. Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
  11. Harry Boxer’s four stocks to watch include cybersecurity company Carbon Black
  12. 4 Stocks Breaking Out On Earnings & Other News
  13. Small-Cap Stocks to Watch in May
  14. What's in the Cards for Fuel Tech (FTEK) in Q1 Earnings?
  15. What's in Store for Axsome (AXSM) This Earnings Season?
  16. Axsome Shares Rally After FDA OKs Expedited Regulatory Filings For Depression Drug
  17. Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
  18. Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting
  19. Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019
  20. 2 Ultra-High Growth Stocks to Buy Now